During the 64th annual meeting of the American Society of Hematology (ASH), held December 10-13 in New Orleans, Louisiana, Roswell Park Comprehensive Cancer Center pre-doctoral trainee Payal Goala, MS, BS, will present research findings that hold potential to help address two significant toxicities associated with Chimeric Antigen Receptor (CAR) T-cell therapy.

Eunice S. Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, led a research effort that supports the addition of gemtuzumab ozogamicin—a CD33-directed antibody-drug conjugate—to standard induction chemotherapy for the treatment of newly-diagnosed intermediate-risk cytogenetic acute myeloid leukemia (AML). The study will be highlighted during an oral presentation at the 64th annual meeting of the American Society of Hematology (ASH), held December 10-13 in New Orleans, Louisiana.

Roswell Park Comprehensive Cancer Center experts from a variety of specialties will share practice-changing discoveries and research advances in hematology and hematologic cancers at the 64th annual meeting of the American Society of Hematology (ASH), held December 10-13 in New Orleans, Louisiana. Roswell Park researchers and physician-scientists in leukemia, lymphoma, and myelodysplastic syndromes were invited to give podium presentations or lead educational sessions during the meeting.

While tobacco smoking has been shown to reduce the efficacy of radiation therapy among patients with head and neck cancers, a new study from Roswell Park Comprehensive Cancer aims to examines cancer treatment outcomes of smokers.

Metastasis, or the spread of cancer cells from a primary tumor to distant organs, lacks effective treatment options and remains a major cause of cancer-related deaths. To better understand how metastasis works — and how it might be controlled — scientists at Roswell Park Comprehensive Cancer Center have zeroed in on the role of the metabolic enzyme 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-4 (PFKFB4) in the spread of triple-negative breast cancer (TNBC). Their study, “Hypoxic activation of PFKFB4 in breast tumor microenvironment shapes metabolic and cellular plasticity to accentuate metastatic competence,” appears today in Cell Reports.

Roswell Park Comprehensive Cancer Center will be well-represented at this week’s 45th annual San Antonio Breast Cancer Symposium (SABCS), running Tuesday through Saturday, December 6-10, at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

A multi-institutional team led by researchers from Roswell Park Comprehensive Cancer Center has identified a novel approach that could potentially improve the efficacy of immune checkpoint inhibitors — a type of immunotherapy — among cancer patients with solid tumors. Findings from this preclinical study demonstrated that the differentiation agent brequinar effectively targeted myeloid-derived suppressor cells (MDSCs) and significantly improved immune checkpoint inhibitor response.